Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Key Stats

• Today's Range: $17.34 to $17.78
• 50-Day Range: $16.34 to $18.97
• 52-Week Range: $8.06 to $19.08
• Volume: 11.15 million shs
• Average Volume: 9.94 million shs
• Market Capitalization: $19.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.89
• Consensus Rating: Moderate Buy

Teva Pharmaceutical Industries Stock Analysis - MarketRank™

Teva Pharmaceutical Industries scored higher than 42% of companies evaluated by MarketBeat, and ranked 687th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Teva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Teva Pharmaceutical Industries has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.88%

Earnings Growth

Earnings for Teva Pharmaceutical Industries are expected to grow by 12.88% in the coming year, from $2.33 to $2.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Teva Pharmaceutical Industries is -42.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Teva Pharmaceutical Industries is -42.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Teva Pharmaceutical Industries has a PEG Ratio of 1.26. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Teva Pharmaceutical Industries has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.11% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.

Short Interest Ratio / Days to Cover

Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Teva Pharmaceutical Industries has recently decreased by 0.17%, indicating that investor sentiment is improving.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Teva Pharmaceutical Industries does not currently pay a dividend.

Dividend Growth

Teva Pharmaceutical Industries does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 38.44% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.11% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.

Short Interest Ratio / Days to Cover

Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Teva Pharmaceutical Industries has recently decreased by 0.17%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.66

News Sentiment

Teva Pharmaceutical Industries has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Teva Pharmaceutical Industries this week, compared to 7 articles on an average week.

Search Interest

85 people have searched for TEVA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $423,263.00 in company stock.

Percentage Held by Insiders

Only 0.55% of the stock of Teva Pharmaceutical Industries is held by insiders.

Percentage Held by Institutions

54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TEVA Stock Analysis - Frequently Asked Questions

How have TEVA shares performed this year?

Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA stock has increased by 67.7% and is now trading at $17.51.
View the best growth stocks for 2024 here.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings results on Wednesday, July, 31st. The company reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.03. The firm earned $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 39.66% and a negative net margin of 2.73%.

Who are Teva Pharmaceutical Industries' major shareholders?

Top institutional investors of Teva Pharmaceutical Industries include Migdal Insurance & Financial Holdings Ltd. (2.57%), Lingotto Investment Management LLP (2.34%), Rubric Capital Management LP (1.52%) and Renaissance Technologies LLC (0.77%). Insiders that own company stock include Roberto Mignone, Mark Sabag, Sven Dethlefs, Eliyahu Sharon Kalif, Richard D Francis, David Matthew Stark, Eric A Hughes, Amir Weiss, Eric Drape, Hafrun Fridriksdottir, Vikki L Conway and Eli Shani.
View institutional ownership trends.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC) and Micron Technology (MU).

Company Calendar

• Last Earnings: 7/31/2024
• Today: 9/22/2024
• Next Earnings (Estimated): 11/13/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:TEVA
• CUSIP: N/A
• CIK: 818686
• Web: www.tevapharm.com
• Phone: (723) 914-8213
• Fax: 972-3923-4050
• Employees: 37,851
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.89
• High Stock Price Target: $26.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +7.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 7.52
• P/E Growth: 1.26
• Net Income: $-559,000,000.00
• Net Margins: -2.73%
• Pretax Margin: -0.87%
• Return on Equity: 39.66%
• Return on Assets: 6.95%

Debt

• Debt-to-Equity Ratio: 2.52
• Current Ratio: 0.89
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: $16.29 billion
• Price / Sales: 1.22
• Cash Flow: $3.41 per share
• Price / Cash Flow: 5.14
• Book Value: $7.25 per share
• Price / Book: 2.42

Miscellaneous

• Outstanding Shares: 1,132,641,000
• Free Float: 1,126,411,000
• Market Cap: $19.83 billion
• Optionable: Optionable
• Beta: 0.88